FIELD: medicine.
SUBSTANCE: group of inventions refers to medicine, and concerns application of compound presented by formula I or its adduct, hydrate or solvate for prevention and / or treatment of obesity. What is also presented is using the compound for treating psoriasis, and gastrointestinal diseases specified in Crohn's disease, colitis, irritable bowel syndrome, diarrhea, nausea and vomiting.
EFFECT: group of inventions provides treating said pathologies, wherein low stability of the compound in blood plasma in humans and various animal species enables to provide an exclusively topical effect, therefore, the compound is safe, id est does not cause systemic by-effects.
6 cl, 7 tbl, 19 ex
| Title | Year | Author | Number |
|---|---|---|---|
| INHIBITORY SOLUTION AND METHOD OF SUPPRESSION OF PAIN, INFLAMMATION OR SPASM | 1995 |
|
RU2180852C2 |
| NOVEL TACHYKININ RECEPTOR ANTAGONIST AND USE THEREOF | 2018 |
|
RU2697414C1 |
| LIGAND WITH WIDE RANGE OF SIMULTANEOUS RECEPTOR ACTIVITY, PHARMACEUTICAL COMPOSITION, METHOD OF PREPARING SAID COMPOSITION AND MEDICINAL AGENT | 2008 |
|
RU2374245C1 |
| SOLUTIONS AND METHODS FOR INHIBITING PAIN, CARTILAGE INFLAMMATION AND DESTRUCTION | 2000 |
|
RU2271825C2 |
| USING CANNABINOIDS COMBINED WITH ANTIPSYCHOTIC DRUG PREPARATION | 2008 |
|
RU2503448C2 |
| MEDICATION BASED ON SUBSTANCE INFLUENCING ENDOCANNABINOID SYSTEM | 2013 |
|
RU2568896C2 |
| METHOD OF TREATING OBESITY AND ACCOMPANYING METABOLIC DISORDERS AND MEDICATION FOR TREATING OBESITY AND ACCOMPANYING METABOLIC DISORDERS | 2010 |
|
RU2552221C2 |
| PHARMACEUTICAL COMPOSITIONS AND THEIR USING IN TREATMENT OF GASTROENTERIC DISEASES | 2000 |
|
RU2264215C2 |
| COMBINATION AND PHARMACEUTICAL PREPARATION FOR TREATMENT OF INFLAMMATORY DISEASES | 2006 |
|
RU2465915C2 |
| PEPTIDE COMPOSITIONS | 2014 |
|
RU2725150C2 |
